HilleVax Reports Full Year 2022 Financial Results and Highlights Recent Company Progress
17. März 2023 16:05 ET
|
HilleVax, Inc.
BOSTON, March 17, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported...
HilleVax Announces Executive Management Appointments and Promotions
09. Januar 2023 07:00 ET
|
HilleVax, Inc.
BOSTON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the...
HilleVax to Present at the 41st Annual J.P. Morgan Healthcare Conference
04. Januar 2023 16:05 ET
|
HilleVax, Inc.
BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...
HilleVax Announces Positive Immunogenicity Results for Run-In Cohort of NEST-IN1 Phase 2b Clinical Trial of HIL-214 Norovirus Vaccine Candidate
05. Dezember 2022 06:30 ET
|
HilleVax, Inc.
BOSTON, Dec. 05, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported results...
HilleVax to Participate in November Investor Conferences
10. November 2022 18:30 ET
|
HilleVax, Inc.
BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...
HilleVax Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
10. November 2022 16:05 ET
|
HilleVax, Inc.
BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial...
HilleVax to Participate in J.P. Morgan Biotech – 2022 Conference Call Series
01. September 2022 17:18 ET
|
HilleVax, Inc.
BOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...
HilleVax Announces Positive Recommendation from Safety Data Monitoring Committee for NEST-IN1 Phase 2b Clinical Trial of HIL-214 Norovirus Vaccine Candidate
31. August 2022 07:00 ET
|
HilleVax, Inc.
Enrollment of remaining subjects in NEST-IN1 has resumed Immunogenicity results from the first 200 subjects expected in Q4 2022 BOSTON, Aug. 31, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc....
HilleVax to Participate in Fireside Chat at the SVB Securities Virtual Vaccine Forum
15. August 2022 07:00 ET
|
HilleVax, Inc.
BOSTON, Aug. 15, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...
HilleVax Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
10. August 2022 16:01 ET
|
HilleVax, Inc.
BOSTON, Aug. 10, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial...